Teriparatide Injection I.P

Teriparatide Injection I.P

Teriparatide is a sterile solution for injection containing Teriparatide (recombinant human parathyroid hormone 1-34). This biologic medication is produced using a strain of E. coli through advanced recombinant DNA technology. The active substance consists of the 34 N-terminal amino acids that mirror the biologically active region of the endogenous 84-amino-acid human parathyroid hormone, making it highly effective in stimulating bone formation.

Category:

Description

Molecular Characteristics:

  • Molecular Weight: 4117.8 Daltons
  • Formulation: Water-soluble protein

Indications: Teriparatide is indicated for the treatment of:

  • Postmenopausal Osteoporosis: Significantly decreases the risk of vertebral and non-vertebral fractures when administered at a daily dose of 20 mcg.
  • Men with Osteoporosis: Designed for men with primary or hypogonadal osteoporosis at high risk for fractures, particularly those who have failed or are intolerant to other available osteoporosis therapies.
  • Glucocorticoid-Induced Osteoporosis: For men and women experiencing osteoporosis associated with sustained systemic glucocorticoid therapy who are at high risk for fracture.

Benefits:

  • Fracture Risk Reduction: Daily administration effectively reduces the incidence of vertebral and non-vertebral fractures in high-risk populations.
  • Bone Mass Increase: Promotes increased bone mass and density, enhancing overall skeletal strength.

Dosage and Administration:

  • Dosage: 20 mcg once daily via subcutaneous injection.
  • Administration Route: Subcutaneous injection in the thigh or abdomen.

Storage:

  • Store in the refrigerator (2°C to 8°C). Do not freeze. Protect from light.

Quality Assurance: Manufactured in FDA-approved facilities following WHO GMP guidelines to ensure the highest standards of quality and safety.

Reviews

There are no reviews yet.

Be the first to review “Teriparatide Injection I.P”

Your email address will not be published. Required fields are marked *